
Hemex Health Inc Profile last edited on: 11/14/2022
CAGE: 7PAA4
UEI: LSJ7WFKBJWW4
Business Identifier: Malaria and sickle cell diagnostic devices Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 01
County: Multnomah
Congr. District: 01
County: Multnomah
Public Profile
Hemex Health is organized around developing technologies to make affordable. life-sustaining medical care possible for people everywhere, no matter how underserved or remote their region. With backgrounds in international business and biomedical engineering, principals of the firm have extensive experience in this arena. The firm's two areas of business focus are global locations tackling elimination of for malaria, and those serving the large populations at risk for sickle cell in the developing world, where few in need are currently tested. In 2016, the firm secured exclusive licenses to technolgy developed by Case Western to develop and commercialize a pair of breakthrough technologies which promise to revolutionize the diagnosis of these two of the worlds most deadly diseases.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
25-49Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2024 | 1 | NIH | $295,920 | |
Project Title: RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay | ||||
2023 | 2 | NIH | $3,720,495 | |
Project Title: HLS-Affordable, Quantitative Microchip-Electrophoresis for Sickle Cell Disease Screening | ||||
2023 | 2 | NIH | $1,955,670 | |
Project Title: Portable, Affordable, Quantitative Microchip Electrophoresis for Hemoglobin A1C Testing | ||||
2021 | 1 | NIH | $256,580 | |
Project Title: Using Multi-Spectral Imaging with Microchip Electrophoresis to Accurately Screen Newborns for Sickle Cell Disease | ||||
2021 | 2 | NIH | $1,668,241 | |
Project Title: Rapid, Point of Care Diagnostic for Malaria, Highly Sensitive for P. Vivax, with Species Differentiation |
Key People / Management
Patti White -- CEO
Daren Bledsoe -- Vice President Engineering
Peter Galen -- CIO
Patricia W Seminario
Gerrit Van Roekel -- Senior VP Business Development
Daren Bledsoe -- Vice President Engineering
Peter Galen -- CIO
Patricia W Seminario
Gerrit Van Roekel -- Senior VP Business Development